Journal of the American Academy of Dermatology
Volume 83, Issue 6, Supplement, December 2020, Page AB140
15026 BMS-986165, an oral selective tyrosine kinase 2 inhibitor: Evaluation of changes in laboratory parameters in response to treatment in a phase 2 trial in psoriasis
References (0)
Cited by (0)
Commercial disclosure: Bristol-Myers Squibb supported the research study and provided medical writing and printing support for this poster.
Copyright © 2020 Published by Mosby, Inc.